Total Funding
86
22
Total FundingPost-IPO Equity raised
Growth Score
-3 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
244679
Genetic Technologies is a molecular diagnostics company specializing in oncology.
- Mike Tonroe: Chief Financial OfficerPast Role: Opthea, CFO
- Nicholas Mark Murphy: Senior Development Scientist
About the Company
Genetic Technologies is a global molecular diagnostic business with an extensive range of international patents and a portfolio of tests and related services.
Our aim is simple: to concentrate on markets where we can establish a long-term dominant position by providing tests that genuinely affect clinical outcomes. We are already the leading
non-government genetic testing business in Australia, and through our wholly owned subsidiary Phenogen Sciences, we now have a solid and growing presence in the USA.
We remain committed to the development of a global portfolio of cancer management tests. The first of which is the Breast Cancer Risk Assessment Test, BREVAGenTM.
